Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial-Reference-Cited by-同舟云学术

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

Published:2010-10 Issue:10 Volume:11 Page:942-949
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Le Cesne Axel,Ray-Coquard Isabelle,Bui Binh Nguyen,Adenis Antoine,Rios Maria,Bertucci François,Duffaud Florence,Chevreau Christine,Cupissol Didier,Cioffi Angela,Emile Jean-François,Chabaud Sylvie,Pérol David,Blay Jean-Yves

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours;Hirota;Science,1998

2. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor;Heinrich;J Clin Oncol,2003

3. Diagnosis of gastrointestinal stromal tumors: a consensus approach;Fletcher;Hum Pathol,2002

4. PDGFRA activating mutations in gastrointestinal stromal tumors;Heinrich;Science,2003

5. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial;Verweij;Lancet,2004

Cited by 244 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Untargeted metabolomics analysis reveals the potential mechanism of imatinib-induced skin rash in patients with gastrointestinal stromal tumor;International Immunopharmacology;2024-10

2. Imatinib in advanced GIST: if it's working, don’t stop a good thing;The Lancet Oncology;2024-09

3. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial;The Lancet Oncology;2024-09

4. A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.;Annals of Oncology;2024-09

5. Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer;JAMA Oncology;2024-07-01